Truxima (rituximab-abbs) is a brand-name intravenous (IV) injection that’s prescribed for rheumatoid arthritis and other conditions. The cost of the drug, with and without insurance, can depend on ...

Truxima (rituximab-abbs) is a brand-name drug that’s prescribed for certain blood cancers, rheumatoid arthritis, and other conditions in adults. As with other drugs, Truxima can cause side effects, ...

Celltrion's blood cancer treatment Truxima (ingredient name: rituximab) has maintained the top spot in prescriptions in the ...

Truxima (rituximab-abbs) is prescribed to treat certain cancers and immune system conditions. The drug is a liquid that a healthcare professional injects into a vein. Doctors determine the dosing ...

Truxima is a biosimilar version of the brand-name drug Rituxan. Biosimilars tend to be less expensive than their brand-name versions. Doctors prescribe Truxima to treat conditions such as rheumatoid ...

(HealthDay)—Truxima (rituximab-abbs) has been approved by the U.S. Food and Drug Administration as the first biosimilar to the non-Hodgkin's lymphoma drug Rituxan, the agency said Wednesday. A ...

TRUXIMA is also now available for the treatment of Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) Rheumatoid Arthritis (RA) in combination with ...

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) and Celltrion Healthcare have launched Truxima Injection in the United States for the treatment of Rheumatoid Arthritis. Truxima is also now ...

Celltrion’s blood cancer treatment Truxima has become the first Korean biosimilar to top its segment in the United States life sciences market and is now the most prescribed rituximab drug in the ...

Celltrion said Wednesday that its blood cancer treatment Truxima received interchangeability designation from the US Food and Drug Administration, becoming the ...

Celltrion announced Tuesday that the US Food and Drug Administration has granted interchangeability status to Truxima (rituximab), its blood cancer treatment. T ...

Biosimilar competition to Roche’s big-selling Rituxan has arrived in the US, with Teva gearing up to launch its Truxima rival at a 10% discount following FDA approval. Truxima – originally developed ...